Rapid Dose Therapeutics Corp. (CSE:DOSE)
Canada
· Delayed Price · Currency is CAD 0.1550
-0.0050 (-3.13%)
At close: Dec 5, 2025
Rapid Dose Therapeutics Income Statement
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Aug '25 Aug 31, 2025 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 | Feb '21 Feb 28, 2021 | 2018 - 2020 |
| Revenue | 2.63 | 2.09 | 1.02 | 0.72 | 1.75 | 0.76 | Upgrade
|
| Revenue Growth (YoY) | 95.76% | 104.34% | 42.06% | -59.00% | 131.98% | 644.05% | Upgrade
|
| Cost of Revenue | 1.26 | 0.91 | 0.46 | 0.36 | 0.41 | 0.13 | Upgrade
|
| Gross Profit | 1.36 | 1.18 | 0.56 | 0.36 | 1.34 | 0.63 | Upgrade
|
| Selling, General & Admin | 3.34 | 3.55 | 2.45 | 2.46 | 2.99 | 1.5 | Upgrade
|
| Research & Development | 0.1 | 0.15 | 0.43 | 0.09 | 0.36 | 0.09 | Upgrade
|
| Operating Expenses | 4.77 | 5.35 | 3.65 | 3.9 | 5.65 | 2.26 | Upgrade
|
| Operating Income | -3.41 | -4.17 | -3.09 | -3.54 | -4.3 | -1.63 | Upgrade
|
| Interest Expense | -1.19 | -1.23 | -0.66 | -0.26 | -0.13 | -0.14 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -0 | 0.02 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | 0.01 | - | Upgrade
|
| EBT Excluding Unusual Items | -4.6 | -5.4 | -3.75 | -3.81 | -4.4 | -1.81 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -4.08 | - | Upgrade
|
| Other Unusual Items | - | - | -0.56 | - | - | - | Upgrade
|
| Pretax Income | -4.6 | -5.4 | -4.31 | -3.81 | -8.49 | -1.81 | Upgrade
|
| Net Income | -4.6 | -5.4 | -4.31 | -3.81 | -8.49 | -1.81 | Upgrade
|
| Net Income to Common | -4.6 | -5.4 | -4.31 | -3.81 | -8.49 | -1.81 | Upgrade
|
| Shares Outstanding (Basic) | 140 | 125 | 105 | 103 | 100 | 78 | Upgrade
|
| Shares Outstanding (Diluted) | 140 | 125 | 105 | 103 | 100 | 78 | Upgrade
|
| Shares Change (YoY) | 33.83% | 18.68% | 1.50% | 3.19% | 28.83% | 2.23% | Upgrade
|
| EPS (Basic) | -0.03 | -0.04 | -0.04 | -0.04 | -0.08 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.04 | -0.04 | -0.04 | -0.08 | -0.02 | Upgrade
|
| Free Cash Flow | -1.06 | -1.15 | -2.29 | -0.86 | -3.04 | -1.63 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.01 | -0.03 | -0.02 | Upgrade
|
| Gross Margin | 51.92% | 56.59% | 55.21% | 49.67% | 76.76% | 83.40% | Upgrade
|
| Operating Margin | -129.74% | -200.07% | -302.45% | -493.36% | -245.55% | -216.45% | Upgrade
|
| Profit Margin | -175.00% | -259.18% | -422.03% | -530.42% | -484.47% | -239.04% | Upgrade
|
| Free Cash Flow Margin | -40.20% | -55.27% | -224.91% | -120.27% | -173.52% | -216.20% | Upgrade
|
| EBITDA | -3.05 | -3.95 | -2.75 | -3.2 | -3.82 | -1.25 | Upgrade
|
| EBITDA Margin | -116.29% | -189.66% | -269.93% | - | -218.31% | -165.21% | Upgrade
|
| D&A For EBITDA | 0.35 | 0.22 | 0.33 | 0.34 | 0.48 | 0.39 | Upgrade
|
| EBIT | -3.41 | -4.17 | -3.09 | -3.54 | -4.3 | -1.63 | Upgrade
|
| EBIT Margin | -129.74% | -200.07% | - | - | -245.55% | -216.45% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.